A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)

Status:

Recruiting

III

Phase

1st+

Line of Therapy

Relapsed / Recurrent / Refractory

Disease Stage

Biomarker(s)

PD-L1

Investigational

Product

Nivolumab

Treatment Arms

o Experimental: Arm A: nivolumab

o Placebo Comparator: Arm B: placebo +BCG